BiotechTube

Moderna mRNA-1273 COVID-19 vaccine + Pfizer BNT162b2 COVID-19 vaccine

ApprovedCompleted
0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Covid19

Conditions

Covid19

Trial Timeline

Aug 25, 2021 → Dec 21, 2022

NCT ID
NCT04969250

About Moderna mRNA-1273 COVID-19 vaccine + Pfizer BNT162b2 COVID-19 vaccine

Moderna mRNA-1273 COVID-19 vaccine + Pfizer BNT162b2 COVID-19 vaccine is a approved stage product being developed by Allergy Therapeutics for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT04969250. Target conditions include Covid19.

What happened to similar drugs?

3 of 15 similar drugs in Covid19 were approved

Approved (3) Terminated (5) Active (9)
✅Icosapent ethylAmarin CorporationApproved
✅bamlanivimabEli LillyApproved
✅COVID-19 vaccine Pfizer (3 doses) + COVID-19 vaccine Pfizer (2 doses) + COVID-19 mRNA Vaccine Moderna (3 doses) + COVID-19 mRNA Vaccine Moderna (2 doses) + COVID-19 mRNA Vaccine Moderna (1 dose)SanofiApproved
❌AVIGAN + Placebo ComparatorDr. Reddy's LaboratoriesPhase 3
❌BaricitinibEli LillyPhase 3
🔄LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814Eli LillyPhase 3
🔄Remdesivir + Remdesivir Placebo + CorticosteroidGilead SciencesPhase 3

Hype Score Breakdown

Clinical
20
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04969250ApprovedCompleted

Competing Products

20 competing products in Covid19

See all competitors
ProductCompanyStageHype Score
AVIGAN + Placebo ComparatorDr. Reddy's LaboratoriesPhase 3
29
Favipiravir + NitazoxanideStrides PharmaPhase 2
35
Icosapent ethylAmarin CorporationApproved
25
GX-03 + Petrolatum ointmentTurn TherapeuticsPhase 2
25
Cytotoxic T LymphocytesTevogen BioPhase 1
19
DS-5670a + PlaceboDaiichi SankyoPhase 1/2
32
Pegylated Interferon-α2bZydus LifesciencesPhase 2
27
BaricitinibEli LillyPhase 3
32
LY3819253 + Placebo + Remdesivir + VIR-7831 + BRII-196/BRII-198 + AZD7442 + MP0420 + PF-07304814Eli LillyPhase 3
40
bamlanivimabEli LillyApproved
35
1x10^9 vp AZD1222 + 5x10^9 vp AZD1222 + 1x10^10 vp AZD1222AstraZenecaPhase 1
25
Sacubitril / Valsartan Oral Tablet [Entresto] + PlaceboNovartisPhase 1/2
32
PirfenidoneRochePre-clinical
26
Remdesivir + Remdesivir Placebo + CorticosteroidGilead SciencesPhase 3
40
RemdesivirGilead SciencesPre-clinical
26
Remdesivir + Remdesivir Placebo + Aviptadil + Aviptadil Placebo + CorticosteroidGilead SciencesPhase 3
40
anti-COVID19 mRNA-based vaccine (BNT162b2, Comirnaty®, commercialized by Pfizer)PfizerPhase 3
36
Pfizer/BioNTech BNT162b2 mRNA COVID-19 vaccine + CoronaVac COVID-19 vaccine + ChAdOx1 nCoV-19 Covid-19 Vaccine + Ad26.COV2.S COVID-19 VaccinePfizerPre-clinical
26
Tofacitinib 10 mg + PlaceboPfizerPhase 3
40
BNT162b2PfizerPhase 2
35